Xinqing Lin
A5015033018- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Viral-associated cancers and disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Polyomavirus and related diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- CAR-T cell therapy research
- Metastasis and carcinoma case studies
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Obstructive Pulmonary Disease (COPD) Research
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Neutropenia and Cancer Infections
- Tumors and Oncological Cases
- Cancer-related Molecular Pathways
First Affiliated Hospital of Guangzhou Medical University
2017-2025
State Key Laboratory of Respiratory Disease
2013-2025
Guangzhou Medical University
2013-2025
Beijing Normal University
2024
National Clinical Research
2020-2023
ShenZhen People’s Hospital
2023
First Affiliated Hospital of Anhui Medical University
2023
Anhui Medical University
2023
Southern Medical University
2020-2022
Nanjing General Hospital of Nanjing Military Command
2009-2020
To understand the molecular mechanism of tumorigenesis pulmonary lymphoepithelioma-like carcinoma and explore potential therapeutic strategies, we investigated genomic profiles PD-L1 expression 29 Chinese patients at various stages. We performed capture-based targeted sequencing on tissue samples collected from 27 with sufficient using a panel consisting 520 cancer-related genes, spanning 1.64 Mb human genome. identified 184 somatic mutations in 109 genes 26 patients. One patient had no...
Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs). However, the roles played by peripheral blood parameters in CIP development remain unclear. Here, we aimed to identify which biomarkers correlated and prognosis of patients lung cancer.We conducted retrospective analysis 87 (CIP group) without (control group). Cytokines, routine, lactate dehydrogenase (LDH) albumin (ALB)...
Abstract Objectives Our research aimed to evaluate the effectiveness of first‐line immune checkpoint inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer (ES‐SCLC) identify prognostic factors, as real‐world outcomes inconsistency PD‐1 PD‐L1 are uncertain. Methods We selected ES‐SCLC patients in three centers conducted a propensity score‐matched analysis. The Kaplan–Meier method Cox proportional hazards regression were compare survival outcomes. also...
Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for less than 1% all tumors. The incidence TETs is about 3.93/10000 in China, slightly higher that European and American countries. For resectable TETs, complete surgical resection recommended. Radiotherapy or chemotherapy may be used as postoperative adjuvant treatment. Treatment advanced, unresectable consist mainly radiotherapy chemotherapy, but there lack standard first- second-line treatment...
Abstract Objective NUT midline carcinoma (NMC), a rare type of squamous cell carcinoma, is genetically characterised by family member 1 (NUTM1) gene rearrangement. NMC can arise from the lungs; however, there no standard for management primary pulmonary NMC. This study aimed to confirm clinical features and report treatments, especially with immune checkpoint inhibitors (ICIs), outcomes patients Methods A retrospective review was performed in First Affiliated Hospital Guangzhou Medical...
Immune checkpoint inhibitors (ICIs) have significant therapeutic effects but can also cause fatal lung injury. However, the lack of mouse animal models ICI-related injury (ICI-LI) has limited in-depth exploration its pathogenesis. In clinical practice, underlying diseases increase risk Thus, we used a model induced by bleomycin (BLM) and then administered anti-programmed cell death 1 (aPD-1) antibodies to induce ICI-LI. Compared with BLM group, aPD-1 + group presented more weight loss,...
This paper reviews the clinical progress achieved in 2024 field of advanced non-small cell lung cancer (NSCLC), both nationally and internationally. In area targeted therapy, particularly for rare mutations, new targets beyond EGFR, ALK, ROS1 such as KRAS G12C, HER2, MET, have gained more validation approval drugs 2024. G12C inhibitors also shown significant improvements disease control rates patients. Novel dual-target are increasingly attracting increasing attention, these target primary...
Circulating tumor cells (CTCs) represent a collection of heterogeneous cells. Studies have shown epithelial CTCs and folate receptor (FR) positive could be used as diagnostic biomarkers for lung cancer (LC). This study aimed to determine whether cell surface vimentin (CSV) biomarker LC well.78 treatment-naïve non-small-cell (NSCLC) patients, 21 patients with benign diseases (BLD) 9 healthy donors (HD) were enrolled in this study. CTC detection was performed using CytoSorter® mesenchymal kit...
Background While immune checkpoint inhibitors (ICIs) are a beacon of hope for non-small cell lung cancer (NSCLC) patients, they can also cause adverse events, including inhibitor pneumonitis (CIP). Research shows that the inflammatory microenvironment plays vital role in development CIP. However, (IME) CIP is still unclear. Methods We collected cohort NSCLC patients treated with ICIs included eight individuals (CIP group) and 29 without (Control group). CIBERSORT xCell algorithm were used to...
Background and Objective Immune checkpoint inhibitor (ICI)-associated myocarditis is a fatal immune-related adverse events (irAEs), which prone to affecting multiple organ systems. Multi-organ irAEs have not been fully studied in ICI-associated myocarditis. Therefore, we aimed explore the impact of multi-organ on ICI terms clinical features, treatment, prognosis. Methods This was retrospective study. The data patients were collected from 6 hospitals China. risk factors characteristics pure...
Abstract Background The treatment of extensive stage small‐cell lung cancer (ES‐SCLC) has only made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, approved for SCLC by January 2022. However, currently, there is limited real‐world data on ES‐SCLC patients received immunotherapy. Methods We retrospectively collected analyzed demographic at First Affiliated Hospital Guangzhou Medical University from 2017 to Survival prognosis...
Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to insidious onset strong local invasiveness of MPM, most patients are diagnosed late stage early screening treatment for high-risk populations crucial. The MPM mainly includes surgery, chemotherapy, radiotherapy. Immunotherapy electric field therapy have also applied, leading further improvements patient survival. Mesothelioma Group Yangtze River...
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell-surface molecules responsible for transmitting signals that regulate cell growth differentiation. In non-small lung cancer (NSCLC), RET fusion a rare driver alteration associated with poor prognosis. Fortunately, two selective inhibitors (sRETi), namely pralsetinib selpercatinib, have been approved treating NSCLC due to their remarkable efficacy safety profiles. These shown ability overcome...
Abstract The fusion genes NRG1 and NRG2, members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, retains its EGF-like active domain, binds to ERBB ligand triggers intracellular signaling cascades, promoting uncontrolled cell proliferation. incidence gene varies across cancer types, with lung being most prevalent at 0.19 0.27%. CD74 SLC3A2 are frequently observed partners. RNA-based next-generation sequencing is primary method for...
Clinical Practice Points•Genetic alterations in v-Raf murine sarcoma viral oncogene homolog B (BRAF), including V600E, are implicated as bypass mechanisms developing resistance to osimertinib; however, treatment strategies that simultaneously target concomitant actionable mutations BRAF and epidermal growth factor receptor (EGFR) remain limited.•A combination of osimertinib vemurafenib was administered third-line therapy two patients with advanced lung adenocarcinoma after V600E identified...
Background Rearranged during transfection (RET) fusion is a kind of uncommon mutation (about 1%) in non-small cell lung cancer (NSCLC). Although selective tyrosine kinase inhibitors (TKI) (selpercatinib and pralsetinib) have been available, there are no real-world data about the difference efficacy between RET-TKI other regimens China. Methods We conducted multicenter retrospective analysis 49 patients with RET-fusion-positive NSCLC. The characteristics clinical outcomes RET-TKI,...
Background: Tracheal adenoid cystic carcinoma (TACC) is the second most common type of cancer in bronchial tumors with poor prognosis. Studies on genomic profiles and tumor immune microenvironment (TIME) TACC are still relatively rare. Methods: Here, we performed whole-exome sequencing (WES), T cell repertoire (TCR) sequencing, immunohistochemistry (IHC) resected matched peripheral blood leukocytes (PBLs) samples from 25 TACCs collected April-2010 to Mar-2019. Results: WES results revealed...
Abstract Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation migration, survival. Its alterations, mainly including mutations, amplifications, overexpression are associated with poor prognosis one of the major drivers non–small lung cancer (NSCLC). Several clinical trials had been investigating on treatments HER2‐altered NSCLC, conventional chemotherapy, programmed death 1 (PD‐1) inhibitors, inhibitors (TKIs)...